Toward Microfluidic Reactors for Cell-Free Protein Synthesis at the Point-of-Care.

Cell-free protein synthesis (CFPS) is a powerful technology that allows for optimization of protein production without maintenance of a living system. Integrated within micro and nanofluidic architectures, CFPS can be optimized for point-of-care use. Here, the development of a microfluidic bioreactor designed to facilitate the production of a single-dose of a therapeutic protein, in a small footprint device at the point-of-care, is described. This new design builds on the use of a long, serpentine channel bioreactor and is enhanced by integrating a nanofabricated membrane to allow exchange of materials between parallel "reactor" and "feeder" channels. This engineered membrane facilitates the exchange of metabolites, energy, and inhibitory species, and can be altered by plasma-enhanced chemical vapor deposition and atomic layer deposition to tune the exchange rate of small molecules. This allows for extended reaction times and improved yields. Further, the reaction product and higher molecular weight components of the transcription/translation machinery in the reactor channel can be retained. It has been shown that the microscale bioreactor design produces higher protein yields than conventional tube-based batch formats, and that product yields can be dramatically improved by facilitating small molecule exchange within the dual-channel bioreactor.

[1]  Z. Hugh Fan,et al.  Fabrication optimization of a miniaturized array device for cell‐free protein synthesis , 2011, Electrophoresis.

[2]  C. Choi,et al.  A Semicontinuous Prokaryotic Coupled Transcription/Translation System Using a Dialysis Membrane , 1996, Biotechnology progress (Print).

[3]  G. Kramer,et al.  High efficiency cell-free synthesis of proteins: refinement of the coupled transcription/translation system. , 1992, Analytical biochemistry.

[4]  J. Swartz,et al.  Advances in Escherichia coli production of therapeutic proteins. , 2001, Current opinion in biotechnology.

[5]  M. Jewett,et al.  Rapid Expression and Purification of 100 nmol Quantities of Active Protein Using Cell‐Free Protein Synthesis , 2008, Biotechnology progress.

[6]  T. Jones,et al.  The side-effect profile of GM-CSF , 2005, Infection.

[7]  A. Spirin,et al.  A continuous cell-free translation system capable of producing polypeptides in high yield. , 1988, Science.

[8]  Volker Dötsch,et al.  Advances in cell-free protein synthesis for the functional and structural analysis of membrane proteins. , 2011, New biotechnology.

[9]  Dong-Myung Kim,et al.  Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli , 2000, Biotechnology Letters.

[10]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[11]  L J Millet,et al.  Modular microfluidics for point-of-care protein purifications. , 2015, Lab on a chip.

[12]  Scott T Retterer,et al.  Fabrication of nanoporous membranes for tuning microbial interactions and biochemical reactions. , 2015, Journal of vacuum science and technology. B, Nanotechnology & microelectronics : materials, processing, measurement, & phenomena : JVST B.

[13]  Vincent Noireaux,et al.  Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription-translation system. , 2014, Biochimie.

[14]  Peter G. Shankles,et al.  Characterization of extended channel bioreactors for continuous-flow protein production , 2015 .

[15]  M. Miller,et al.  A mass spectrometric method for quantitation of intact insulin in blood samples. , 2001, Journal of analytical toxicology.

[16]  C. J. Murray,et al.  Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production—A New Approach for Shortening Protein Production Development Timelines , 2011, Biotechnology and bioengineering.

[17]  M. Jewett,et al.  Substrate replenishment extends protein synthesis with an in vitro translation system designed to mimic the cytoplasm , 2004, Biotechnology and bioengineering.

[18]  D. Prazeres Prediction of diffusion coefficients of plasmids. , 2008, Biotechnology and bioengineering.

[19]  Rui Gan,et al.  Cell-free protein synthesis: applications come of age. , 2012, Biotechnology advances.

[20]  David J Beebe,et al.  Cell-free protein expression in a microchannel array with passive pumping. , 2009, Lab on a chip.

[21]  Junhao Yang,et al.  Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. , 2007, Blood.

[22]  V. Dötsch,et al.  Preparative scale cell-free expression systems: new tools for the large scale preparation of integral membrane proteins for functional and structural studies. , 2007, Methods.

[23]  Dong-Myung Kim,et al.  Prolonging Cell‐Free Protein Synthesis by Selective Reagent Additions , 2000, Biotechnology progress.

[24]  K. Yoshikawa,et al.  Cell-Sized confinement in microspheres accelerates the reaction of gene expression , 2012, Scientific Reports.

[25]  C. Bokemeyer,et al.  Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer , 1993, Annals of Hematology.

[26]  Dong-Myung Kim,et al.  Prolonging cell-free protein synthesis with a novel ATP regeneration system. , 1999, Biotechnology and bioengineering.

[27]  J. Swartz,et al.  Development of cell‐free protein synthesis platforms for disulfide bonded proteins , 2008, Biotechnology and bioengineering.

[28]  M. Jewett,et al.  Mimicking the Escherichia coli cytoplasmic environment activates long‐lived and efficient cell‐free protein synthesis , 2004, Biotechnology and bioengineering.

[29]  R. Khnouf,et al.  Cell‐Free Protein Synthesis in Microfluidic Array Devices , 2007, Biotechnology progress.

[30]  Dong-Myung Kim,et al.  Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis. , 2001, Biotechnology and bioengineering.

[31]  Piro Siuti,et al.  Continuous protein production in nanoporous, picolitre volume containers. , 2011, Lab on a chip.

[32]  H. Ng,et al.  Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients , 2006, Vascular health and risk management.

[33]  C. Richardson,et al.  Conformational dynamics of bacteriophage T7 DNA polymerase and its processivity factor, Escherichia coli thioredoxin , 2010, Proceedings of the National Academy of Sciences.

[34]  Lizhong He,et al.  A Novel Correlation for Protein Diffusion Coefficients Based on Molecular Weight and Radius of Gyration , 2003, Biotechnology progress.

[35]  Chung-Jr Huang,et al.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements , 2012, Journal of Industrial Microbiology & Biotechnology.

[36]  S. Scott Dose Conversion from Recombinant Human Erythropoietin to Darbepoetin alfa: Recommendations From Clinical Studies , 2002, Pharmacotherapy.